Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelicapavir for RSV Infection in High-Risk Adults
NCT07908381Phase 3Recruiting
- Sponsor
- Enanta Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 3 trial of zelicapavir in respiratory syncytial virus infection (RSV), sponsored by Enanta Pharmaceuticals. Started Oct 2026; status: recruiting.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07908381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908381.